India’s Emcure Launches First Generic of Eisai's Halaven, Changing Pricing Scenario
Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.
You may also be interested in...
India’s Intas Launches Trastuzumab At A 65% Discount
India’s Intas Pharmaceuticals will undercut domestic rivals by marketing its new biosimilar trastuzumab at a price 65% cheaper than the current market cost.
Can Emcure’s Cut-Price Eribulin Dull Halaven In India?
Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.
Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India
Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.